Drugs commonly used for rheumatism and possible adverse effects

Rheumatism is a chronic, autoimmune disease, and many people are not well informed about the drug, and the usual treatments and possible adverse effects for Rheumatism are as follows:Inflammatory drugs (NSAIDs)• Drugs commonly used: Brophen, bichlorfonic acid, neptunium, saliva, etc. • Mechanisms of action: Reduction of prostate synthesis by inhibiting the activity of the cyclic oxidation enzymes (COX), which acts as an anti-inflammation, dermalization and pain-repression mechanism. • Negative response: gastrointestinal reaction: most commonly manifested in nausea, vomiting, abdominal pain, diarrhoea, indigestion, stomach ulcer, haemorrhage and even perforation. Of these, there is a relatively high incidence of gastrointestinal adverse effects of traditional non-selective NSAIDs (e.g. Brophen, dichlorophenic acid, etc.) and a relatively low incidence of gastrointestinal malformations of selective COX-2 inhibitors (e.g., sieves) but there are risks associated with long-term use. Cardiovascular system: Some NSAIDs may increase the risk of cardiovascular infarction, e.g., myocardial infarction, mediocre, especially when used at long, large doses. Kidney damage: can cause sodium sodium in the water, incomplete kidneys, etc., and is more likely to occur among the elderly and those suffering from pre-existing kidney diseases. Other: There may also be adverse effects such as dizziness, ringing in the ear, rashes, liver damage, but relatively few. DMARDs• Drugs commonly used: traditional synthesis of DMARDs: ammonium butterflies, fluoride, nitrous sulfon, hydroxychloride, etc. Biological agent DMARDs: Oncological cause of death-alpha (TNF-alpha) inhibitors (e.g. Innasip, Innflict, Adam, etc.), white cellulin-6 (IL-6) inhibitors (e.g. beads standoff), anti-CD20 antibodies (e.g. Littos standoff). Targets are synthesized in DMARDs: e.g. Janus Stimulator (JAK) inhibitors (Cartini, Barretini, etc.). • Mechanisms of action: Traditional synthetic DMARDs can regulate immune response, contain inflammation and delay joint destruction through a variety of mechanisms; biological agents DMARDs are primarily designed to function for specific cytogens or cytological surface markers, and more precisely to disrupt the path to inflammation; target-oriented DMARDs regulate the function of immune cells by inhibiting specific enzymes. • Adverse effects: traditional synthesis of DMARDs: ▪caraminos: common adverse effects include gastrointestinal reactions (e.g., nausea, vomiting, oral ulcer, etc.), damage to the liver function, bone marrow inhibition (in the form of white cells, reduced blood panels, etc.), loss of hair, etc. In addition, long-term use may increase the risk of lung disease (e.g., IMTS). • Flammet: adverse effects such as gastrointestinal reaction (e.g., nausea, vomiting, diarrhoea), damage to liver function, hair loss, rash, etc. • Nitrogen sulfon: The gastrointestinal reaction is more pronounced, such as nausea, vomiting, abdominal pain, diarrhoea, and can also result in rashes, changes in the blood system (e.g. reduction of white cells, anaemia, etc.). ▪羟: Relatively less adverse effects, mainly gastrointestinal (e.g., nausea, vomiting, diarrhoea), eye toxicity (e.g., retinal pathology, which may occur at long, large doses and requires regular eye examinations). Biological agent DMARDs: ▪ TNF-α inhibitors: generally, it is safe, but there may be adverse reactions such as inoculations (e.g., edema, pain, itching, etc.), increased risk of infection (e.g., bacteria, viruses, fungi infections, etc., especially tuberculosis infections, which require tuberculosis screening prior to use), re-emergence of self-immunological diseases (e.g., systematic erythalamus use may lead to a relapse). ▪ IL-6 inhibitors: There may be adverse effects such as increased risk of infection (e.g. bacteria, viruses, fungi infections, etc.), gastrointestinal reaction (e.g. nausea, vomiting, diarrhoeal diseases, etc.) and damage to liver function. Anti-CD20 antibodies: Common adverse effects include aqueous response (e.g. heat, cold warfare, rash, itching, etc.), increased risk of infection (e.g. bacteria, viruses, fungi infections, etc.), changes in the blood system (e.g. reduction of white cells, reduction of platelets, etc.). Targets to synthesized DMARDs: ▪ JAK inhibitors: There is a risk of an increased risk of infection (e.g. bacteria, viruses, fungi infections, etc.), gastrointestinal reaction (e.g., nausea, vomiting, diarrhoea, etc.), damage to the liver function, changes in the blood system (e.g., reduction of white cells, reduction of slabs, etc.), haemoglobin abnormalities (e.g., rise of cholesterol, triester). Sugar cortex hormones• Drugs commonly used: Pohneson, Captron, etc. • Mechanisms of action: Strong anti-inflammation, immunosuppression, etc., which can rapidly reduce the symptoms of joint pain, swelling, etc. • Negative effects: metabolic disorders: can lead to increased blood sugar, increased blood pressure, increased blood resin, obese heart (expressed in the face, neck, abdominal obesity, and relatively thin limbs). Osteoporosis: Long-term use leads to bone loss and increases the risk of osteoporosis and fracture. A digestive system: There may be gastrointestinal reactions (e.g., nausea, vomiting, abdominal pain, etc.) and an increased risk of ulcer, haemorrhage and perforation of the stomach. Immunosuppression: Reducing the immune capacity of the organism and increasing the vulnerability of patients to bacteria, viruses and fungi. Moral symptoms: Some patients may suffer from mental disorders such as stress, anxiety, depression, insomnia, etc. Eye damage: Long-term use can lead to eye diseases such as glaucoma, cataracts, etc. The treatment of rheumatism requires a combination of the patient ‘ s condition, age and physical condition, the choice of the appropriate drug, and close attention to the adverse response of the drug, as well as timely access to care in order to adjust the treatment programme in a timely manner.